With our AI-enabled drug discovery platform and the dedication of our brilliant, hard-working team, we have developed differentiated therapies for some of the most challenging and pervasive diseases — at record pace.
We’re immensely proud of how far we’ve come since our founding in 2019. And we’re just getting started.
Mechanism: Novel Anti-Inflammatory
Indication: Atopic Dermatitis
ENV-294 is a first-in-class oral small molecule, with Jak-inhibitor-like efficacy and IL4/IL13-like safety, targeting atopic dermatitis and other inflammatory conditions. We believe ENV-294 has pipeline-in-a-product potential. ENV-294 is currently in Phase 1 clinical trials.
Mechanism: Novel Anti-Inflammatory
Indication: Immuno-inflammatory diseases
ESN-X is a first-in-class, gut-preferred oral small molecule that offers a "multi-biologic in a pill" potential for the treatment of inflammatory bowel disease. ESN-X has completed IND-enabling studies and is expected to enter Phase 1 trials in 2025.
ENV-294 is a first-in-class oral small molecule, with Jak-inhibitor-like efficacy and IL4/IL13-like safety, targeting atopic dermatitis and other inflammatory conditions. We believe ENV-294 has pipeline-in-a-product potential. ENV-294 is currently in Phase 1 clinical trials.
ESN-X is a first-in-class, gut-preferred oral small molecule that offers a "multi-biologic in a pill" potential for the treatment of inflammatory bowel disease. ESN-X has completed IND-enabling studies and is expected to enter Phase 1 trials in 2025.
Development Candidate Declared
THE PROBLEM
Over 10% (30M+) of the US population suffers from atopic dermatitis, commonly known as eczema. Yet, today’s treatments for moderate-to-severe eczema either rely on injectables that pose a significant barrier to patient care or oral therapies that come with potentially serious toxicities. Moreover, despite these treatments, half of all eczema to atopic dermatitis patients respond poorly to therapy.
THE MOLECULE
We are developing a first-in-class medicine that fights inflammation in a new way. This novel mechanism allows it to exert potentially powerful anti-inflammatory effects without the same toxicities that have burdened previous treatments - and can be delivered orally via a pill.
THE PROGRESS
Our molecule has demonstrated robust efficacy comparable to Jak-inhibitors in preclinical atopic dermatitis models but without their concomitant risks as evidenced by pre-clinical safety testing. It is currently in Phase I clinical trials.
THE PROBLEM
Inflammatory bowel disease, or IBD, which includes both Crohn's disease and Ulcerative Colitis, is a chronic autoimmune disorder that damages the digestive tract and disrupts the lives of more than 3 million people in the United States. IBD has limited treatment options that have proven to cause long-term remission in patients.
Moreover, many safe existing treatments have to be delivered as injections or pills that come with significant safety liabilities.
THE MOLECULE
We are developing a new therapeutic approach to treating IBD. Our first-in-class molecule hits multiple clinically validated pathways simultaneously, has been engineered to be preferentially present in the gut, and can be administered as a convenient pill. With ESN-X, we have the potential to deliver improved safety, efficacy, and convenience.
THE PROGRESS
This powerful molecule is set to enter clinical trials in 2025.
Together, we can rapidly multiply humanity’s knowledge of the natural
world’s chemistry and solve many of the greatest challenges in human
and planetary health. We’d love your support.